CTOs on the Move

Sienna Biopharmaceuticals

www.siennabio.com

 
Sienna Biopharmaceuticals is focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes, and physicians’ practice of medicine.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.siennabio.com
  • 30721 Russell Ranch Road Suite 140
    Westlake Village, CA USA 91362
  • Phone: 818.629.2256

Executives

Name Title Contact Details

Funding

Sienna Biopharmaceuticals raised $34M on 04/28/2016

Similar Companies

Olink Proteomics

Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements

PDL BioPharma

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has invested approximately $780 million to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its shareholders. The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.

Ben Venue-Bedford Laboratories

Ben Venue-Bedford Laboratories, Inc. is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BIOMERIX

BIOMERIX is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vericel

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous cellularized scaffold product that is indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing 1 additional cell product. Ixmyelocel-T is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Developing autologous (patient`s own) cell therapies—with integrity Vericel uses rigorous scientific methods to develop novel therapies for the treatment of patients with autologous (patient`s own) cells. In addition, personal integrity, team work, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us.